Status:
COMPLETED
A Drug Interaction Study of SPD503 and Vyvanse Administered Alone and In Combination in Normal Healthy Volunteers
Lead Sponsor:
Shire
Conditions:
Healthy
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
Drug-drug interaction study; to examine the pharmacokinetics of SPD503 and VYVANSE (lisdexamfetamine dimesylate) when given alone, and in combination.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Subjects must be normal healthy adult volunteers (with no significant abnormalities in medical history, physical exam, vital signs or lab evaluations at screening) in order to be eligible to participate.
Exclusion
Key Trial Info
Start Date :
June 24 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 30 2009
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT00919867
Start Date
June 24 2009
End Date
July 30 2009
Last Update
June 14 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Advanced Biomedical Research, Inc.
Hackensack, New Jersey, United States